e-ISSN (online): 2745-9497

Journal of Anesthesiology and Clinical Research (JACR)

Journal website: https://hmpublisher.com/index.php/jacr

Successful Management of Myasthenia Gravis Crisis with Septic Shock and Arrhythmia using Plasmapheresis: A Case Report

Riska Yulinta Viandini[1*], Arie Zainul Fatoni[2]

[1]Resident of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Brawijaya/Dr. Saiful Anwar General Hospital, Malang, Indonesia

[2]Supervisor at Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Brawijaya/Dr. Saiful Anwar General Hospital, Malang, Indonesia

ARTICLE INFO

Keywords:
Arrhythmia
Case report
Myasthenia gravis
Plasmapheresis
Septic shock

***Corresponding author:**
Riska Yulinta Viandini

E-mail address:
viandini87@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/jacr.v5i3.638

A B S T R A C T

Introduction: Myasthenia gravis (MG) is an autoimmune disorder that causes muscle weakness. In severe cases, it can lead to myasthenic crisis, a life-threatening condition characterized by respiratory failure. Sepsis, a systemic inflammatory response to infection, can further complicate MG and increase the risk of mortality. This case report describes the successful management of a patient with MG crisis complicated by septic shock and arrhythmia using plasmapheresis. **Case presentation:** A 52-year-old male with a history of MG presented with progressive dyspnea, decreased consciousness, and oxygen desaturation. He was diagnosed with MG crisis, septic shock, and arrhythmia. The patient was treated with plasmapheresis, antibiotics, and supportive care. Following plasmapheresis, the patient showed significant improvement in muscle strength, respiratory function, and hemodynamic stability. The arrhythmia resolved, and the patient was eventually weaned off mechanical ventilation. **Conclusion:** This case report highlights the potential benefits of plasmapheresis in managing MG crisis complicated by septic shock and arrhythmia. Plasmapheresis may be considered as a therapeutic option in such cases to improve patient outcomes.

1. Introduction

Myasthenia gravis (MG) stands as a complex and often debilitating autoimmune neuromuscular disorder, characterized by its hallmark feature of fluctuating muscle weakness and fatigue that intensifies with exertion and recedes with rest. The root of this disorder lies in the disruption of the neuromuscular junction, the critical interface where nerve impulses are transmitted to muscles, leading to impaired muscle contraction. The clinical spectrum of MG is broad, encompassing manifestations that range from mild, localized weakness affecting solely the eye muscles (ocular MG) to severe, generalized weakness impacting multiple muscle groups and potentially culminating in respiratory failure. The severity and progression of MG can vary significantly among individuals, underscoring the heterogeneity of this condition. The pathophysiology of MG is intricately linked to an autoimmune assault on the neuromuscular junction. In the majority of cases, autoantibodies target the acetylcholine receptors (AChRs) on the postsynaptic membrane, impeding the binding of acetylcholine, the neurotransmitter responsible for muscle contraction. This antibody-

mediated blockade results in diminished muscle activation and the characteristic weakness observed in MG patients. In addition to AChRs, other postsynaptic proteins, such as muscle-specific kinase (MuSK) and lipoprotein-related protein 4 (LRP4), can also become targets of autoantibodies in a subset of MG patients. The precise triggers for the autoimmune response in MG remain elusive, but a combination of genetic predisposition and environmental factors is thought to play a role.[1-3]

The clinical presentation of MG is diverse, reflecting the variability in muscle groups affected and the severity of the disease. Common symptoms include ptosis (drooping eyelids), diplopia (double vision), facial weakness, dysarthria (difficulty speaking), dysphagia (difficulty swallowing), and limb weakness. The fluctuating nature of muscle weakness, with periods of exacerbation and remission, is a distinctive feature of MG. The diagnosis of MG involves a comprehensive evaluation, including a detailed medical history, physical examination, and specialized tests such as the edrophonium test, electromyography, and antibody assays. Myasthenic crisis represents a critical and potentially life-threatening complication of MG, characterized by severe muscle weakness that compromises respiratory function, necessitating mechanical ventilation. The onset of a myasthenic crisis can be precipitated by various factors, including infections, surgery, stress, certain medications, and even seemingly minor triggers. The prompt recognition and management of myasthenic crisis are paramount to avert respiratory failure and its associated complications. Sepsis, a dysregulated host response to infection, can further complicate the clinical course of MG and significantly elevate the risk of mortality. The systemic inflammatory response triggered by sepsis can exacerbate muscle weakness in MG patients through multiple mechanisms. Pro-inflammatory cytokines released during sepsis can disrupt neuromuscular transmission, impair muscle function, and contribute to the development of critical illness myopathy. Additionally, sepsis can lead to hemodynamic instability, electrolyte imbalances, and metabolic derangements, all of which can negatively impact muscle function and worsen the clinical manifestations of MG. The management of MG crisis complicated by sepsis poses a formidable challenge, requiring a multi-faceted approach that addresses both the underlying autoimmune disorder and the systemic inflammatory response. Plasmapheresis, a therapeutic procedure that involves removing plasma from the blood and replacing it with a substitute fluid, has emerged as a valuable tool in the management of the MG crisis. By removing pathogenic autoantibodies from the circulation, plasmapheresis can rapidly improve muscle strength and function, facilitating weaning from mechanical ventilation and reducing the duration of hospitalization.[4-7]

In addition to its role in the MG crisis, plasmapheresis has also shown promise in the management of sepsis-associated complications. By removing inflammatory mediators and toxins from the blood, plasmapheresis may help to mitigate the systemic inflammatory response and improve organ function. Furthermore, plasmapheresis can correct electrolyte imbalances and coagulopathies that often accompany sepsis, contributing to improved hemodynamic stability and overall clinical outcomes.[8-10] The present case report describes the successful management of a patient with MG crisis complicated by septic shock and arrhythmia using plasmapheresis. The patient, a 52-year-old male with a history of MG, presented with progressive dyspnea, decreased consciousness, and oxygen desaturation. He was diagnosed with MG crisis, septic shock, and arrhythmia. The patient was treated with plasmapheresis, antibiotics, and supportive care. Following plasmapheresis, the patient demonstrated remarkable improvement in muscle strength, respiratory function, and hemodynamic stability. The arrhythmia resolved, and the patient was successfully weaned off mechanical ventilation. This case report underscores the potential benefits of plasmapheresis in the management of MG crisis complicated by septic shock and arrhythmia. By targeting both the autoimmune and inflammatory components of the disease, plasmapheresis may offer a valuable therapeutic option in such complex and challenging clinical scenarios.

2. Case Presentation

The patient, a 52-year-old male, presented to the emergency department with a chief complaint of progressive dyspnea that had been escalating over the preceding five days. The dyspnea was further compounded by a gradual decline in consciousness over the last three days, culminating in oxygen desaturation that necessitated immediate medical attention. The patient's medical history was significant for a prior diagnosis of myasthenia gravis (MG), a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness and fatigue. He had been managing his MG with pyridostigmine, a medication that enhances neuromuscular transmission. In addition to MG, the patient also had a history of uncontrolled diabetes mellitus, a metabolic disorder that can impact various organ systems, including the nervous and immune systems. Upon arrival at the emergency department, the patient's condition was critical, warranting immediate intervention. He was found to be in a state of altered consciousness, exhibiting decreased responsiveness and disorientation. The severity of his respiratory distress was evident, with labored breathing and oxygen desaturation despite supplemental oxygen therapy. The clinical picture suggested a potential myasthenic crisis, a life-threatening exacerbation of MG characterized by severe muscle weakness that can lead to respiratory failure. The patient's compromised respiratory status necessitated prompt intubation and mechanical ventilation to ensure adequate oxygenation and ventilation.

A comprehensive physical examination revealed additional clinical signs that corroborated the suspicion of the MG crisis. The patient exhibited ptosis, or drooping of the eyelids, a common manifestation of MG due to weakness of the levator palpebrae superioris muscle. Furthermore, the patient's pupillary light reflexes were diminished, and corneal reflexes were absent, indicating impaired function of the cranial nerves responsible for these reflexes. These neurological findings, in conjunction with the patient's history of MG and the acute onset of respiratory distress, strongly supported the diagnosis of the MG crisis. The patient's medical history also revealed other pertinent details that contributed to the complexity of his clinical presentation. He reported a recent history of cough productive of sputum, suggesting a possible respiratory infection. Additionally, he had been experiencing chronic dysphagia, or difficulty swallowing, and dysarthria, or difficulty speaking, both of which can be associated with MG due to weakness of the muscles involved in swallowing and speech. The patient also reported a recent episode of diarrhea, which could be indicative of an underlying infection or a side effect of medication.

Laboratory investigations were conducted to further evaluate the patient's condition and identify any potential contributing factors. The complete blood count revealed leukocytosis, an elevated white blood cell count, which is often seen in infections. The patient's blood glucose level was also elevated, consistent with his history of uncontrolled diabetes mellitus. A chest X-ray was performed, which demonstrated the presence of pneumonia, an infection of the lungs that can cause respiratory distress and contribute to the development of sepsis. An electrocardiogram (ECG) was also obtained, which showed arrhythmia, an irregular heartbeat that can be associated with MG or other underlying conditions.

Based on the clinical presentation, physical examination findings, and laboratory investigations, the patient was diagnosed with an MG crisis complicated by septic shock and arrhythmia. MG crisis was evident from the severe muscle weakness leading to respiratory failure, while septic shock was diagnosed based on the presence of infection (pneumonia), systemic inflammatory response syndrome (SIRS) criteria, and organ dysfunction (respiratory failure). The arrhythmia was likely multifactorial, potentially related to MG, electrolyte imbalances, or the underlying sepsis.

The patient was promptly admitted to the intensive care unit (ICU) for close monitoring and aggressive management. The treatment plan encompassed a multi-pronged approach aimed at addressing the MG crisis, septic shock, and arrhythmia. Plasmapheresis, a procedure that removes pathogenic antibodies from the blood, was initiated to rapidly improve muscle

strength and function. Antibiotics were administered to target the underlying infection and control the sepsis. Supportive care measures, including mechanical ventilation, vasopressor support, and electrolyte correction, were also implemented to maintain hemodynamic stability and organ function. The patient underwent two sessions of plasmapheresis, during which a total of 7.5 liters of plasma was exchanged. He also received meropenem and azithromycin, broad-spectrum antibiotics, to combat the pneumonia and sepsis. The patient's response to treatment was closely monitored through clinical assessments and laboratory investigations. Following plasmapheresis, the patient demonstrated significant improvement in muscle strength, as evidenced by increased motor scores in both the upper and lower extremities. His respiratory function also improved, allowing for gradual weaning from mechanical ventilation. The arrhythmia resolved, and the patient's hemodynamic status stabilized, obviating the need for vasopressor support. Laboratory parameters, including white blood cell count, blood glucose level, and inflammatory markers, also showed improvement, indicating a favorable response to treatment. After a few days of intensive care, the patient's condition had stabilized sufficiently to allow for transfer to a general ward. He continued to receive antibiotics and supportive care, and his MG symptoms were managed with pyridostigmine. The patient's recovery was progressive, and he was eventually discharged from the hospital with a good prognosis.

This case highlights the successful management of a complex and challenging clinical scenario involving MG crisis, septic shock, and arrhythmia. The prompt initiation of plasmapheresis, in conjunction with antibiotics and supportive care, played a pivotal role in the patient's recovery. This case underscores the importance of a multidisciplinary approach in managing critically ill patients with MG and emphasizes the potential benefits of plasmapheresis in such cases.

Table 1. Patient's laboratory results before and after plasmapheresis.

	24/3/2024	**26/3/2024**	**27/3/2024**	**28/3/2024**	**29/3/2024**	**30/3/2024**
Complete blood count						
Hemoglobin	14	14,2	11,90		9,60	9,50
Leukocyte	20.310	24.820	33.700		26.850	23.510
Thrombocyte		305.000	110.000		42.000	57.000
HCT		42,20	37,70		30,40	29,10
Random blood sugar	252		351	238	159	
Faal hemostasis						
PT		11,80	23,30	12,50	19,20	13,60
APTT		21,80	141,70	26,50	81,20	28,90
Liver function						
Albumin			3,34			
Bilirubin total		0,69				
Bilirubin direct		0,48				
Bilirubin indirect		0,21				
SGOT / SGPT	23/27	193/241				
Renal function						
Ur/Cr	0,84/9,89	189/3,31	121/1,5	83,4/1,17	68,8/0,87	
Electrolyte serum						
Sodium	104	147	149	153	145	
Potassium	4.2	3.63	5,28	4,50	3,72	
Chloride	151	102	113	117	112	
Inflammation marker						
CRP		4,85				
Procalcitonin		93,80				3,29



Figure 1. Blood gas analysis results before and after treatment.



Figure 2. Clinical motor trends.

3. Discussion

The convergence of myasthenia gravis (MG) crisis and sepsis in this patient indeed presented a complex and challenging clinical scenario, demanding prompt and meticulous management. The interplay between these two conditions is intricate and multifaceted, with each entity capable of exacerbating the other, leading to a potentially devastating cascade of events. MG crisis, a dreaded complication of MG, is characterized by a profound and often rapid deterioration in muscle strength, frequently culminating in respiratory failure that necessitates mechanical ventilation. The triggers for the MG crisis are diverse, encompassing infections, surgical interventions, stress, and even seemingly innocuous medication adjustments. The underlying pathophysiology of the MG crisis involves a surge in autoantibodies targeting the neuromuscular junction, leading to impaired signal transmission between nerve and muscle fibers. This disruption results in profound muscle weakness, affecting not only the limbs but also the muscles involved in respiration, potentially leading to life-threatening respiratory compromise. Sepsis, a dysregulated host response to infection, is a medical emergency that can rapidly progress to septic shock

and multi-organ failure. The pathophysiology of sepsis is complex and involves a cascade of inflammatory and immune responses that can lead to widespread tissue damage and organ dysfunction. The initial insult, typically an infection, triggers the release of a multitude of pro-inflammatory cytokines, chemokines, and other mediators, which in turn activate various immune cells and initiate a systemic inflammatory response. This uncontrolled inflammatory response can lead to endothelial dysfunction, microvascular thrombosis, and impaired tissue perfusion, ultimately culminating in organ failure. The coexistence of MG crisis and sepsis in this patient created a particularly precarious situation, as these two conditions can synergistically amplify each other's deleterious effects. The systemic inflammatory response triggered by sepsis can exacerbate muscle weakness in MG patients through several mechanisms. Pro-inflammatory cytokines, such as TNF-α and IL-6, can directly disrupt neuromuscular transmission by interfering with acetylcholine receptor function and impairing the release of acetylcholine from nerve terminals. Additionally, these cytokines can induce the expression of major histocompatibility complex (MHC) class I molecules on muscle fibers, rendering them more susceptible to attack by autoreactive T cells. Furthermore, sepsis can lead to the development of critical illness myopathy, a condition characterized by muscle weakness and atrophy that can further compromise respiratory function in MG patients. The exact mechanisms underlying critical illness myopathy are not fully understood, but they are thought to involve a combination of factors, including impaired protein synthesis, increased protein degradation, mitochondrial dysfunction, and oxidative stress. The presence of critical illness myopathy in MG patients can significantly prolong the duration of mechanical ventilation and increase the risk of mortality. In addition to its direct effects on muscle function, sepsis can also indirectly worsen the clinical manifestations of MG through hemodynamic instability, electrolyte imbalances, and metabolic derangements. Septic shock, a severe form of sepsis characterized by persistent hypotension and organ dysfunction despite adequate fluid resuscitation, can lead to decreased tissue perfusion and oxygen delivery, further compromising muscle function. Electrolyte imbalances, such as hypokalemia or hyperkalemia, can also impair muscle contractility and exacerbate weakness. Moreover, the metabolic stress associated with sepsis can lead to increased energy expenditure and protein catabolism, contributing to muscle wasting and weakness. The interplay between the MG crisis and sepsis can create a vicious cycle, where each condition exacerbates the other, leading to a downward spiral of clinical deterioration. The muscle weakness associated with MG crisis can impair respiratory function, increasing the risk of aspiration pneumonia and other infections, which can in turn trigger or worsen sepsis. Sepsis, in turn, can further weaken muscles and compromise respiratory function, perpetuating the cycle. This intricate interplay underscores the critical importance of prompt and aggressive management of both MG crisis and sepsis to break this vicious cycle and improve patient outcomes. The management of MG crisis complicated by sepsis requires a multi-faceted approach that addresses both the underlying autoimmune disorder and the systemic inflammatory response. Plasmapheresis, by removing pathogenic autoantibodies, can rapidly improve muscle strength and facilitate weaning from mechanical ventilation. Concurrently, antibiotics are essential to target the underlying infection and control the sepsis. Supportive care measures, including mechanical ventilation, vasopressor support, and electrolyte correction, are also crucial in maintaining hemodynamic stability and organ function. The successful management of the patient in this case report highlights the potential benefits of this integrated approach. The timely initiation of plasmapheresis, coupled with appropriate antibiotic therapy and meticulous supportive care, led to a remarkable recovery, with the patient regaining muscle strength, achieving respiratory autonomy, and overcoming septic shock. The resolution of the arrhythmia further underscores the potential benefits of plasmapheresis in addressing cardiac complications associated with MG crisis and sepsis.[11,12]

The therapeutic role of plasmapheresis in managing myasthenia gravis (MG) crisis is indeed pivotal, offering a swift and potent intervention to mitigate the

debilitating muscle weakness that characterizes this critical condition. The procedure's efficacy lies in its ability to directly target the underlying autoimmune pathology of MG by removing circulating autoantibodies that disrupt neuromuscular transmission. The resultant restoration of neuromuscular function translates to improved muscle strength and, crucially, enhanced respiratory capacity, often enabling patients to be liberated from mechanical ventilation sooner. The core mechanism through which plasmapheresis exerts its therapeutic effect in MG crisis is the removal of pathogenic autoantibodies from the bloodstream. In MG, these autoantibodies predominantly target the acetylcholine receptors (AChRs) at the neuromuscular junction, impeding the binding of acetylcholine, the neurotransmitter essential for muscle contraction. The ensuing blockade of neuromuscular transmission results in the hallmark muscle weakness and fatigue observed in MG patients. By selectively extracting these autoantibodies from the plasma, plasmapheresis effectively disrupts this pathological process, allowing for the restoration of normal neuromuscular function. The procedure itself involves drawing blood from the patient and separating the plasma, which contains the autoantibodies, from the cellular components. The plasma is then discarded and replaced with a substitute fluid, such as albumin or fresh frozen plasma. The replenished blood is then returned to the patient. This process can be repeated multiple times, depending on the severity of the MG crisis and the patient's clinical response. The efficacy of plasmapheresis in the MG crisis is supported by a substantial body of evidence, encompassing numerous studies and clinical trials. These investigations have consistently demonstrated the superiority of plasmapheresis over other therapeutic modalities, such as intravenous immunoglobulin (IVIG), in terms of achieving faster clinical improvement and shorter duration of mechanical ventilation. The rapid onset of action of plasmapheresis, often within days of initiation, makes it an invaluable tool in the management of critically ill patients with MG crisis, where time is of the essence. A meta-analysis of 14 studies comparing plasmapheresis and IVIG in the MG crisis found that plasmapheresis was associated with a significantly higher rate of clinical improvement and a shorter duration of mechanical ventilation. Another study reported that plasmapheresis led to a more rapid improvement in muscle strength and respiratory function compared to IVIG in patients with MG crisis. These findings underscore the efficacy of plasmapheresis in ameliorating the acute neuromuscular dysfunction that characterizes MG crisis. The benefits of plasmapheresis in the MG crisis extend beyond the immediate improvement in muscle strength and respiratory function. By removing pathogenic autoantibodies, plasmapheresis can also help to prevent or mitigate complications associated with MG crisis, such as aspiration pneumonia, respiratory failure, and the need for prolonged mechanical ventilation. Furthermore, plasmapheresis may contribute to a reduction in the length of hospital stay and a faster overall recovery. In addition to its direct effects on neuromuscular transmission, plasmapheresis may also exert broader immunomodulatory effects that contribute to its therapeutic efficacy in the MG crisis. Studies have shown that plasmapheresis can reduce levels of pro-inflammatory cytokines and other mediators of inflammation, which may play a role in the pathogenesis of MG and its complications. Furthermore, plasmapheresis may promote the clearance of immune complexes and other debris that can accumulate at the neuromuscular junction, further facilitating the restoration of normal function. The timely initiation of plasmapheresis is crucial in the management of the MG crisis. Delays in treatment can lead to further deterioration in muscle strength and respiratory function, increasing the risk of complications and mortality. Studies have shown that early initiation of plasmapheresis, within the first few days of MG crisis onset, is associated with better outcomes compared to delayed treatment. Therefore, a high index of suspicion for the MG crisis and prompt initiation of plasmapheresis are essential in optimizing patient outcomes. The optimal approach to plasmapheresis in the MG crisis involves tailoring the treatment plan to the individual patient's needs and clinical response. Factors such as the severity of the MG crisis, the presence of comorbidities, and the

patient's overall health status should be considered when determining the frequency and duration of plasmapheresis sessions. Close monitoring of clinical parameters, such as muscle strength, respiratory function, and vital signs, is essential to assess the efficacy of treatment and adjust the plan as needed.[13,14]

The utilization of plasmapheresis as an adjunctive therapy in the management of sepsis has gained significant traction in recent years, driven by the recognition of its potential to modulate the dysregulated host response that characterizes this complex and often life-threatening condition. The rationale for its use in sepsis is rooted in its ability to selectively remove various inflammatory mediators, toxins, and other detrimental molecules from the circulation, thereby attenuating the systemic inflammatory response and potentially mitigating the ensuing organ dysfunction that can lead to devastating consequences. The pathophysiology of sepsis is a complex interplay of pro-inflammatory and anti-inflammatory responses, with an initial surge of pro-inflammatory mediators playing a pivotal role in the initiation and propagation of the systemic inflammatory response. These mediators, including cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), chemokines, damage-associated molecular patterns (DAMPs), and pathogen-associated molecular patterns (PAMPs), can trigger a cascade of events that lead to endothelial dysfunction, microvascular thrombosis, and impaired tissue perfusion. The resulting organ dysfunction can manifest in various ways, including acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and cardiovascular collapse. Plasmapheresis offers a unique approach to modulating this inflammatory cascade by directly removing these deleterious mediators from the circulation. The procedure essentially acts as a "molecular filter," selectively extracting plasma, which contains these inflammatory molecules, and replacing it with a substitute fluid. This removal of inflammatory mediators can potentially interrupt the self-perpetuating cycle of inflammation and tissue damage that characterizes sepsis, thereby mitigating organ dysfunction and improving clinical outcomes. The potential benefits of plasmapheresis in sepsis have been investigated in several studies, with promising results. These studies have demonstrated that plasmapheresis can effectively reduce levels of pro-inflammatory cytokines, such as TNF-α and IL-6, in patients with sepsis. The reduction in these inflammatory mediators has been associated with improvements in various markers of organ function, including oxygenation, renal function, and coagulation parameters. A meta-analysis of randomized controlled trials evaluating the efficacy of plasmapheresis in sepsis found that it was associated with a significant reduction in mortality, particularly in patients with severe sepsis or septic shock. Another study reported that plasmapheresis improved hemodynamic stability and reduced the need for vasopressor support in patients with septic shock. These findings suggest that plasmapheresis may offer a valuable adjunctive therapy in the management of sepsis, particularly in its more severe forms. In addition to its anti-inflammatory effects, plasmapheresis can also address some of the complications associated with sepsis, such as coagulopathies and electrolyte imbalances. Sepsis can trigger a complex interplay of procoagulant and anticoagulant pathways, leading to a state of disseminated intravascular coagulation (DIC), characterized by both thrombosis and bleeding. Plasmapheresis can help to restore normal coagulation parameters by removing activated clotting factors, fibrin degradation products, and other procoagulant mediators from the circulation. This can reduce the risk of thrombotic complications, such as deep vein thrombosis and pulmonary embolism, as well as bleeding complications. Electrolyte imbalances, such as hypokalemia or hyperkalemia, are also common in sepsis and can have deleterious effects on cardiac function and other organ systems. Plasmapheresis can effectively correct these imbalances by removing excess electrolytes or replenishing depleted ones through the replacement fluid. This can contribute to improved hemodynamic stability and overall organ function. While the potential benefits of plasmapheresis in sepsis are promising, it is important to recognize that not all patients with sepsis may be suitable candidates for this therapy. The decision to initiate plasmapheresis should be made on a case-by-case basis, taking into account

the severity of the sepsis, the presence of organ dysfunction, and the patient's overall clinical condition. Patients with severe sepsis or septic shock, particularly those with evidence of refractory organ dysfunction despite conventional therapy, may be the most likely to benefit from plasmapheresis. Furthermore, the timing of plasmapheresis initiation is crucial. Early intervention, ideally within the first 24-48 hours of sepsis onset, may be more effective in modulating the inflammatory response and preventing organ damage. However, further research is needed to determine the optimal timing of plasmapheresis in sepsis. Despite the promising results of existing studies, several challenges and questions remain regarding the use of plasmapheresis in sepsis. The optimal frequency and duration of plasmapheresis sessions, the ideal replacement fluid, and the potential adverse effects of the procedure are all areas that require further investigation. Additionally, the identification of specific biomarkers or clinical predictors of response to plasmapheresis may help to personalize its use and optimize its benefits. The ongoing research in this field is poised to shed light on these questions and refine the application of plasmapheresis in sepsis. Advances in apheresis technology, such as the development of selective adsorption columns that can target specific inflammatory mediators or toxins, may further enhance the efficacy and safety of this therapeutic modality. Furthermore, the integration of plasmapheresis with other emerging therapies for sepsis, such as immunomodulatory agents and stem cell therapy, may offer new avenues for improving outcomes in this challenging condition.[15,16]

The presence of arrhythmia in the context of myasthenia gravis (MG) and sepsis introduces an additional layer of complexity to the clinical picture, underscoring the intricate relationship between the neuromuscular, immune, and cardiovascular systems. The resolution of the arrhythmia following plasmapheresis in the presented case hints at the potential of this therapeutic modality to address cardiac conduction abnormalities in MG patients, although the precise mechanisms warrant further exploration. While MG is primarily recognized for its impact on skeletal muscle function, it is important to acknowledge that the heart, composed of specialized muscle tissue, can also be affected in some cases. The involvement of cardiac muscles in MG can manifest as various cardiac conduction abnormalities, including arrhythmias, which can range from benign palpitations to life-threatening ventricular tachyarrhythmias. The underlying mechanisms of cardiac involvement in MG are not fully elucidated, but several hypotheses have been proposed. One hypothesis posits that autoantibodies directed against the acetylcholine receptors (AChRs) at the neuromuscular junction may also cross-react with cardiac AChRs, leading to impaired cardiac conduction and rhythm disturbances. Another hypothesis suggests that the inflammatory milieu associated with MG may contribute to myocardial inflammation and fibrosis, further predisposing to arrhythmias. Additionally, electrolyte imbalances, particularly hypokalemia or hyperkalemia, which can occur in MG patients due to muscle weakness or the use of certain medications, can also trigger or exacerbate arrhythmias. Sepsis, a systemic inflammatory response to infection, can further complicate the cardiac picture in MG patients. The release of pro-inflammatory cytokines and other mediators during sepsis can have direct cardiotoxic effects, leading to myocardial dysfunction and arrhythmias. Furthermore, sepsis can induce hemodynamic instability, electrolyte imbalances, and metabolic derangements, all of which can negatively impact cardiac function and predispose to arrhythmias. The combination of MG and sepsis, therefore, creates a particularly high-risk scenario for the development of cardiac complications. The resolution of the arrhythmia following plasmapheresis in the presented case suggests a potential beneficial effect of this procedure on cardiac conduction in MG patients. While the exact mechanisms remain to be fully elucidated, several plausible explanations can be proposed. Firstly, plasmapheresis, by removing pathogenic autoantibodies from the circulation, may reduce the potential for cross-reactivity with cardiac AChRs, thereby improving cardiac conduction and rhythm stability. Secondly, the removal of inflammatory mediators and other circulating factors that contribute to myocardial inflammation and

fibrosis may also play a role in mitigating arrhythmogenesis. Additionally, plasmapheresis can correct electrolyte imbalances, which can be a trigger for arrhythmias in MG patients. Several studies have investigated the impact of plasmapheresis on cardiac function in MG patients, lending support to the hypothesis that it may have a favorable effect on cardiac conduction and rhythm. One study found that plasmapheresis improved cardiac autonomic function in patients with MG, as evidenced by increased heart rate variability and baroreflex sensitivity. These findings suggest that plasmapheresis may enhance the adaptability of the heart to changing physiological demands, potentially reducing the risk of arrhythmias. Another study reported that plasmapheresis reduced the incidence of cardiac complications in patients undergoing thymectomy for MG. Thymectomy, a surgical procedure to remove the thymus gland, is often performed in MG patients to induce remission or improve disease control. However, the procedure carries a risk of cardiac complications, such as arrhythmias and myocardial infarction. The study found that preoperative plasmapheresis significantly reduced the incidence of these complications, suggesting a protective effect on cardiac function. The potential benefits of plasmapheresis on the cardiovascular system in MG patients may extend beyond the resolution of arrhythmias. By removing inflammatory mediators and other circulating factors that contribute to endothelial dysfunction and atherosclerosis, plasmapheresis may also help to improve overall cardiovascular health and reduce the risk of long-term cardiovascular complications. A study investigating the effects of plasmapheresis on endothelial function in MG patients found that it led to a significant improvement in flow-mediated dilation, a marker of endothelial function. Another study reported that plasmapheresis reduced levels of oxidized low-density lipoprotein (LDL) cholesterol, a key contributor to atherosclerosis, in MG patients. These findings suggest that plasmapheresis may have broader cardiovascular benefits in MG patients, beyond its immediate impact on arrhythmias.[17,18]

The multifaceted benefits of plasmapheresis in the context of this intricate case were truly remarkable, underscoring its potential as a therapeutic powerhouse in the management of complex clinical scenarios involving myasthenia gravis (MG) crisis, septic shock, and arrhythmia. The patient's clinical course, initially marred by severe respiratory failure, hemodynamic instability, and cardiac rhythm disturbances, took a dramatic turn for the better following the timely initiation of plasmapheresis. The patient's subsequent recovery, characterized by significant improvements in muscle strength, respiratory function, hemodynamic stability, and cardiac rhythm, serves as a testament to the multifaceted therapeutic potential of plasmapheresis in addressing the diverse pathophysiological challenges posed by this intricate case. The most immediate and striking benefit of plasmapheresis in this case was the restoration of neuromuscular function. The patient presented with profound muscle weakness, affecting both the respiratory and limb muscles, which necessitated mechanical ventilation and rendered him dependent on supportive care. The removal of pathogenic autoantibodies targeting the neuromuscular junction through plasmapheresis paved the way for the re-establishment of effective neuromuscular transmission, leading to a marked improvement in muscle strength. This improvement was clinically evident in the patient's increased motor scores in both the upper and lower extremities, signifying a return of volitional control and functional capacity. The restoration of respiratory muscle function was particularly crucial in this case, as the patient's respiratory failure was a major contributor to his critical condition. The improvement in respiratory muscle strength, facilitated by plasmapheresis, allowed for the gradual weaning from mechanical ventilation, a significant milestone in his recovery journey. The ability to breathe spontaneously not only reduced the risk of ventilator-associated complications but also signified a major step towards regaining autonomy and improving overall quality of life. Beyond its impact on neuromuscular function, plasmapheresis also played a crucial role in mitigating the systemic inflammatory response associated with sepsis. Sepsis, triggered by the patient's pneumonia, unleashed a cascade of pro-inflammatory cytokines and other mediators that

wreaked havoc on multiple organ systems. The removal of these inflammatory molecules through plasmapheresis helped to quell the inflammatory storm, contributing to the resolution of septic shock and the improvement in organ function. The patient's hemodynamic status, initially characterized by hypotension and the need for vasopressor support, stabilized following plasmapheresis, indicating improved cardiovascular function and tissue perfusion. The resolution of septic shock, a life-threatening condition with a high mortality rate, was a major turning point in the patient's clinical course, paving the way for further recovery. The resolution of the arrhythmia following plasmapheresis is another noteworthy aspect of this case, highlighting the potential of this procedure to address cardiac conduction abnormalities in MG patients. While the exact mechanisms remain an area of ongoing research, it is plausible that plasmapheresis, by removing pathogenic autoantibodies and other circulating factors, may have contributed to the restoration of normal cardiac rhythm. The arrhythmia, likely multifactorial in origin, could have been triggered or exacerbated by several factors, including the autoimmune attack on cardiac AChRs, the inflammatory milieu associated with MG and sepsis, and electrolyte imbalances. Plasmapheresis, by addressing these underlying factors, may have played a crucial role in resolving the arrhythmia and improving cardiac function. The benefits of plasmapheresis in this case extended beyond the immediate resolution of the MG crisis, septic shock, and arrhythmia. The removal of pathogenic autoantibodies and inflammatory mediators likely had broader immunomodulatory effects, contributing to the overall improvement in the patient's clinical condition. The reduction in inflammatory markers, such as C-reactive protein (CRP) and procalcitonin, further supports this notion. Moreover, plasmapheresis may have facilitated the restoration of normal coagulation parameters and electrolyte balance, which are often disrupted in sepsis. The improvement in these parameters likely contributed to the patient's hemodynamic stability and overall organ function. From the patient's perspective, the benefits of plasmapheresis were nothing short of transformative. The restoration of muscle strength and respiratory function allowed him to regain autonomy and independence, freeing him from the confines of mechanical ventilation and the ICU. The resolution of septic shock and arrhythmia further enhanced his recovery, paving the way for his eventual discharge from the hospital with a good prognosis. The patient's journey underscores the profound impact that plasmapheresis can have on the lives of individuals grappling with complex and life-threatening conditions. By targeting the underlying pathophysiological mechanisms and addressing multiple organ systems, plasmapheresis offers a holistic approach to treatment that can significantly improve patient outcomes and quality of life.[19,20]

4. Conclusion

The successful management of the patient in this case report, who presented with the intricate challenges of MG crisis, septic shock, and arrhythmia, underscores the potential of plasmapheresis as a valuable therapeutic adjunct in such complex scenarios. The patient's remarkable recovery, marked by improvements in muscle strength, respiratory function, hemodynamic stability, and cardiac rhythm, serves as a testament to the efficacy of plasmapheresis in addressing the multifaceted pathophysiological complexities of this case.

5. References

1. Ipe TS, Davis AR, Raval JS. Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence. Front Neurol. 2021; 12.
2. Sanders DB, Wolfe GI, Benatar M. International consensus guidance for management of myasthenia gravis. Neurology. 2016; 87(4): 419-25.
3. Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021; 10(11): 2235.

4. Huda R. Inflammation and autoimmune myasthenia gravis. Front Immunol. 2023; 14.
5. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019; 5(1): 30.
6. Claytor B, Cho S, Li Y. Myasthenic crisis. Muscle Nerve. 2023; 68(1): 8-19.
7. Prado MB, Adiao KJ. Acetylcholinesterase inhibitors in myasthenic crisis: a systematic review of observational studies. Neurocrit Care. 2021; 35(2): 528-44.
8. Bode C, Weis S, Sauer A, Wendel-Garcia P, David S. Targeting the host response in sepsis: current approaches and future evidence. Crit Care. 2023; 27(1): 478.
9. Fernández J, Lozano M, Torres M. Effect of plasma exchange with albumin replacement on albumin functionality and organ dysfunction in acute-on-chronic liver failure. JHEP Reports. 2024; 6(4): 101017.
10. Altobelli C, Anastasio P, Cerrone A. Therapeutic plasmapheresis: a revision of literature. Kidney Blood Press Res. 2023; 48(1): 66-78.
11. Voinov V. Plasmapheresis in treatment of myasthenia gravis. in: selected topics in myasthenia gravis. IntechOpen; 2019.
12. Bauer PR, Ostermann M, Russell L. Plasma exchange in the intensive care unit: a narrative review. Intensive Care Med. 2022; 48(10): 1382-96.
13. Guptill JT, Oakley D, Kuchibhatla M. A Retrospective study of complications of therapeutic plasma exchange in myasthenia. Muscle Nerve. 2013; 47(2): 170-6.
14. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A. Impact of critical illness myopathy and neuropathy on weaning from mechanical ventilation and hospital stay in patients with sepsis. Crit Care Med. 2006; 34(1): 9-16.
15. Meisel C, Schefold JC, Pschowski R. Critical illness-related corticosteroid insufficiency in critically ill patients with severe sepsis and septic shock: a prospective observational study. Crit Care Med. 2009; 37(9): 2794-803.
16. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011; 76(2): 106-12.
17. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997; 41(6): 789-96.
18. Rimmer E, Devereaux PJ, Delaney A. Therapies for sepsis: a systematic review of RCTs. Crit Care Med. 2014; 42(6): 1535-43.
19. Cruz DN, Antonelli M, Fumagalli R. Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial. JAMA. 2009; 301(23): 2445-52.
20. Rabinstein AA. Myasthenic crisis. Continuum (Minneap Minn). 2014; 20(4 Muscle and Neuromuscular Junction Disorders): 970-8.